![NephroDI Therapeutics Secures Strategic Investment to Propel Innovative Therapy for Pediatric Kidney Disease](https://thetimesmag.com/wp-content/uploads/2024/06/Promo-Facebook-Facebook-right-column-1-600x400.jpeg)
NephroDI Therapeutics Secures Strategic Investment to Propel Innovative Therapy for Pediatric Kidney Disease
NephroDI Therapeutics (NephroDI), a leading near-clinical stage pharmaceutical company specializing in kidney disorders, proudly announces a significant Series A investment from life sciences venture capital firm Sound Bioventures. This latest infusion of capital, in tandem with a previously established strategic corporate partnership, is set to advance the development of NDI-5001, a groundbreaking small molecule AMPK…